Tema Heart & Health ETF
$35.77−0.57 (−1.58%)
- 0.99%
- $54M
- +14.5%
- 1.30%
- 0M sh
- $36.22
- low $31.87high $38.87
The ETF.net HRTS Grade
D
Score 27 out of 100
- 22 of 25
Score 27 of 100 falls in the D band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.
Cost
The fund’s net expense ratio, ranked against its category.F0 out of 100Rank 25 of 25Mission
Whether the fund did what it promised, tested against its stated mandate.A73 out of 100Rank 8 of 11Risk
How the fund held up when markets fell: downside volatility, drawdowns and tail loss.C47 out of 100Rank 14 of 24Tradability
How easy the fund is to trade: daily volume, and how far its price strays from net asset value.D35 out of 100Rank 16 of 25Holdings
How concentrated the fund is, and how complete and current its disclosed holdings are.B66 out of 100Rank 11 of 25Durability
Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.D36 out of 100Rank 20 of 25
Our read on HRTS
DMost health care ETFs buy the whole hospital. HRTS buys the cardiology and metabolic wing: roughly 40 companies that must earn at least half their revenue from treating heart or metabolic disease.
The Fund seeks long-term growth of capital and invests at least 80% of its assets in publicly listed companies deriving at least half of their revenue from cardiovascular- or metabolic-disease treatments.
Why people hold it
- Real purity screen: at least 80% of assets sit in companies drawing half or more of revenue from cardiovascular or metabolic disease treatments. No insurers or dental chains riding along.
- Roughly 40 stocks, so every name carries weight. This is a targeted position on heart and metabolic medicine, not a sector index with a theme sticker on it.
- The portfolio matches what the prospectus promises closely, which is not a given among thematic funds. What you read in the mandate is what shows up in the holdings.
- Launched in 2023 as one of the earlier US funds built purely around the heart and metabolic disease complex, an area usually buried inside broad health care baskets.
Worth knowing
- Specialist pricing: 0.99% a year, against single-digit basis points at broad sector funds like VHT and XLV. That gap is the toll for the curated 40-stock screen.
- Narrow by design. One disease cluster, about 40 names, so it can swing on trial results and pipeline news rather than drifting with the health care sector.
- A small, thinly traded fund. Spreads tend to be wider than at the sector giants, which matters most on large or hurried orders.
HRTS Holdings
- Stocks
- 46
- 47%
- LLY
Sectors
- Health Care100.0%
Geography
- United States79.79%
- Switzerland6.64%
- Denmark4.10%
- United Kingdom2.94%
- Japan2.48%
- Ireland2.22%
- Israel1.27%
- Canada0.55%
HRTS Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
Not enough history yet.Not enough history yet.Not enough history yet.
HRTS$11,446
Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | HRTS |
|---|---|
| Year to date | +3.0% |
| 1 month | +0.9% |
| 3 months | −0.8% |
| 1 year | +14.5% |
| 3 years | — |
| 5 years | — |
| 10 years | — |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | HRTS |
|---|---|---|
| 2026 YTD | +3.0% | |
| 2025 | +23.9% | |
| 2024 | −4.3% | |
| 2023 | +14.9% |
HRTS in the news
HRTS Dividends
- 1.30%
- $0.47
- $0.47 per share
- Annual
Distribution history
HRTS Risk
- 17.7%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.50
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −25.8%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.66
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
HRTS Cost
0.99%
HRTS0.99%
- The middle half of Health Care (Broad) funds
- Median 0.50%
Every other Health Care (Broad) fund charges less.
Other funds in Health Care (Broad)
- DEKGFirst Trust Nasdaq Lux Digital Health Solutions ETFExpense ratio 0.65%1 year return +35.4%
- DMDEVFirst Trust Indxx Medical Devices ETFExpense ratio 0.70%1 year return +5.9%
- DGDOCGoldman Sachs Future Health Care Equity ETFExpense ratio 0.75%1 year return +11.4%
- FKUREKraneShares MSCI All China Health Care Index ETFExpense ratio 0.79%1 year return −1.7%
- FLGHTLangar Global HealthTech ETFExpense ratio 0.85%1 year return +9.0%